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Studies of human papillomaviruses (HPV) are hampered by the lack of a conventional culture system, because HPV
completes its life cycle only in fully differentiated human tissue. To overcome this obstacle, the athymic mouse xenograft
system has been used to study the pathogenesis of a limited number of HPV types. We recently reported the propagation
of a novel HPV type in the mouse xenograft system and the cloning of its genome. Consensus primer PCR had previously
identified this virus as MM7, LVX82, or PAP291. Here we report the nucleotide sequence of the 8104-bp genome of this virus,
now called HPV 83. HPV 83 is most closely related to HPV 61 and HPV 72, placing it in the papillomavirus genome homology
group A3. Based on limited epidemiological data, the histological appearance of infected human foreskin implants, and the
structure of the predicted HPV 83 E7 protein, this virus is probably of at least intermediate cancer risk. Like other
papillomaviruses, HPV 83 produces an E1^E4, E5 transcript, but the position of the splice acceptor differs from that of other
HPVs. The presence of an E5 open reading frame in the HPV 83 genome is uncertain; the most likely candidate to be the HPV
83 E5 protein has some structural similarity to the bovine papillomavirus 1 E5 oncoprotein, and is unlike most other HPV E5
proteins. HPV 83 is a relatively prevalent genital papillomavirus that has the largest genome of any characterized HPV and
several other novel structural features that merit further study. © 1999 Academic Press
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The human papillomaviruses (HPVs) are a ubiquitous
ollection of closely related human pathogens. These
iruses have a number of common features, such as
nfecting epithelial surfaces, but they also have a number
f distinctions. Two commonly made distinctions are the
ype of epithelium typically infected (cutaneous or geni-
al/mucosal) and the most serious anticipated outcome
f infection (benign proliferation or cancer). There are a
umber of differences in the eight proteins encoded by
ost HPVs that may explain some of the biological
istinctions among the types. However, functional differ-
nces of HPV proteins have been examined for only a
imited number of proteins and types, so the biological
onsequences are not fully understood. Most of the pro-
eins that have been studied have been examined in
solation from other HPV proteins in cultured cells be-
ause of the lack of a good laboratory system for grow-
ng HPV. There are probably about 100 distinct HPV
ypes, some of which have not been fully characterized.
We recently propagated a novel genital HPV type us-
ng the athymic mouse xenograft system and cloned the
enome of this HPV (Brown et al., 1998). Human foreskin
mplants removed from mice after 10–12 weeks of growth
1 To whom reprint requests should be addressed at Emerson Hall
B35, 545 Barnhill Drive. Fax: (317) 274-1587. E-mail: kfife@iupui.edu.
165n this system displayed histological abnormalities that
iffered from those induced by HPV 11 in similar im-
lants; differences included less epithelial proliferation
nd foci of dysplastic cells in implants infected with the
ew virus. The genome of this novel HPV, referred to as
PV IU in our original publication (Brown et al., 1998),
epresents the previously uncharacterized type that was
nown as either MM7, LVX82, or PAP291 based on the
52-bp DNA fragment that is amplified using the
Y09/11 consensus PCR primers (Manos et al., 1994;
ng et al., 1994). This novel HPV type has been identified
n about 1% of normal patients in several large popula-
ion surveys and has been found in 0.1–5.2% of cervical
ysplasia and cervical cancer specimens (Becker et al.,
994; Bosch et al., 1995; Schiffman et al., 1993). One
tudy identified this virus in 13.3% of women who were
nfected with the human immunodeficiency virus (HIV)
Shah et al., 1997). In this communication, we report the
ucleotide sequence and unique properties of the
104-bp genome of this virus, now named HPV 83.
RESULTS
equence
Sequencing of the cloned viral DNA revealed a ge-
ome of 8104 bp, making it the largest among charac-
erized genital HPVs. The sequence is available in Gen-
ank under accession number AF151983. The sequence
0042-6822/99 $30.00
Copyright © 1999 by Academic Press
All rights of reproduction in any form reserved.
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166 BROWN ET AL.nd clone were submitted to the Referenzzentrum fu¨r
umanpathogene Papillomviren (Heidelberg, Germany),
nd the virus was assigned the number HPV 83 (E.-M. de
illiers, personal communication). To confirm the larger
ize of the HPV 83 genome, DNA was purified from HPV
1- or HPV 83-infected human foreskin implants, di-
ested with BamHI (a single cut enzyme for both DNAs),
nd run on an agarose gel. A Southern blot of that gel is
hown in Figure 1, demonstrating that the HPV 83 ge-
ome is slightly larger than that of HPV 11. A BLAST
omology search showed that HPV 83 is most closely
elated to HPV 61 (71.2% homology) and HPV 72 (71.4%
omology). HPV 61 and HPV 72 were also identified in
ucosal lesions (Volter et al., 1996) but have not been
ound commonly in surveys of normal or abnormal gen-
tal specimens. This relationship places HPV 83 in the
apillomavirus homology group A3; the sequence frag-
ent of HPV 83 called MM7 had been tentatively placed
n group A3, and this sequence confirms that assignment
see the Los Alamos Papillomavirus Sequence Compen-
ium at http://cds.lanl.gov/HTML_FILES/HPVcompintro4.
tml for current homology information and for summaries
f papillomavirus sequences and homologies).
Examination of the sequence for potential genes
howed the typical complement of papillomavirus open
eading frames (ORFs), with the exception of E5 (see
elow). The putative ORFs are summarized in Table 1.
able 2 shows the relatedness of putative HPV 83 pro-
eins to the analogous proteins of several other papillo-
avirus types. As expected, HPV 83 proteins are pre-
icted to be most closely related to HPV 61 or 72 pro-
eins. Most HPV 83 proteins also were closely related to
omology group A4 HPV types 2A, 27, and 57 proteins.
he relationship with other common HPV types such
FIG. 1. Southern blot of DNA from HPV 11- or HPV 83-infected human
oreskin implants. Lane 1, DNA from an HPV 11-infected implant di-
ested with BamHI; lane 2, DNA from an HPV 83-infected implant
igested with BamHI; lane 3, a mixture of DNA from an HPV 11- and an
PV 83-infected implant digested with BamHI. The blot was probed
ith a mixture of cloned HPV 11 and HPV 83 DNA that was labeled with
2P. The position of size markers (in base pairs) is shown on the left; the
rrows indicate the positions of the two bands.PV 11 and HPV 16 was substantially less. a7 protein homology
Based on available epidemiological evidence, it is not
ertain whether HPV 83 should be classified as a high-
ancer-risk HPV type or as a low-risk type. HPV 83 DNA
identified in those studies as either MM7, LVX82, or
AP291) has been found in some dysplastic cervical
esions and at least one cervical cancer, as well as a
umber of specimens from patients with normal cytology
Becker et al., 1994; Bosch et al., 1995; Schiffman et al.,
993; Shah et al., 1997). Examination of the sequence of
he putative E7 protein may provide some insight into the
redicted biological behavior. Two regions of the E7
rotein have been shown to be critical for transformation,
nd these regions are homologous to the adenovirus
1A protein conserved regions (CR) 1 and 2 (Phelps et
l., 1988). In mutational analyses of the E7 amino-termi-
al region homologous to CR1, four individual residues
ave been defined as critical for immortalization or trans-
ctivation (Davies and Vousden, 1992; Phelps et al., 1992;
atanabe et al., 1990). Eight of the first 17 amino acids of
PV 83 and HPV 16 E7 proteins, including the critical
esidues 2, 10, 13, and 17, are identical, and two others
re conservative changes. Both HPV 11 and HPV 18 E7
TABLE 1
Location of Putative HPV 83 ORFs
Gene Start position First ATG Stop position
E6 8071 1 444
E7 414 420 713
E1 694 718 2673
E2 2576 2615 3757
E4 3138 3153 3494
E5a 4046 4112 4255
L2 4286 4349 5764
L1 5664 5742 7253
oly(A)1signal 4327, 7472 N/A 4333, 7477
a Tentative designation; see text.
TABLE 2
Homology of Putative HPV 83 ORFs with Those of Other HPVs
Homology with HPV 83 (%)a
E6 E6 E1 E2 E4 L2 L1
PV 61 65 61 75 61 54 68 80
PV 72 63 62 74 62 50 72 81
PV 2a 49 47 64 52 43 68 67
PV 27 51 48 64 51 42 67 67
PV 57 50 46 64 52 41 69 68
PV 11 37 47 53 44 35 48 62
PV 16 38 43 53 40 31 50 63
a The putative HPV 83 E5 protein has no sequence homology with
ny other HPV E5 protein.
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167HPV 83 NUCLEOTIDE SEQUENCEroteins share similar numbers of amino acids with the
PV 16 protein, but neither is a perfect match at all four
ritical positions. An alignment of the critical pRB binding
egion (analogous to CR2) of HPV 83 E7 with those of
ther HPV types is shown in Figure 2. The presence of
he aspartic acid residue just before the characteristic
-X-C-X-E motif is more common in high-risk HPV types
han in low-risk types and has been associated with
ncreased affinity for pRB binding and increased trans-
orming activity (Gage et al., 1990; Heck et al., 1992; Sang
nd Barbosa, 1992; Takami et al., 1992).
FIG. 2. Alignment of putative E7 proteins around the pRB binding site.
he consensus pRB binding sequence is blocked. The amino acid
efore the pRB binding site (underlined) has been shown to be critical
or pRB binding affinity.
FIG. 3. (a) Possible E5 ORFs contained in the region between the en
arly polyadenylation signal is not shown. The putative protein labeled
he carboxyl-terminus. The numbers to the left of the ORF arrows indic
5 protein made from the E5c ORF above is shown. Shown below is theittle true sequence homology, but they are of similar size and both contain a5 ORF
One of the regions of HPV 83 DNA that accounts for
he larger size compared with some other HPVs is the
egion between the end of the E2 ORF and the beginning
f the L2 ORF that usually contains the E5 ORF plus
ome cis elements, such as the early polyadenylation
ignal. In HPV 83 DNA, this distance is 592 bp compared
ith 384 bp in HPV 16, 330 bp in HPV 18, and 330 bp in
PV 31. However, the comparable distance is 582 bp in
PV 11 and 549 bp in HPV 6, so some types do contain
E5” regions of similar length. Despite this elongated
egion, HPV 83 DNA contains no ORF in this area that
ncodes a potential E5 protein with any homology to a
nown papillomavirus E5 protein. A search of this region
or potential ORFs reveals four stretches of sequence
hat could encode proteins of less than 100 amino acids
ach. One of these potential ORFs extends beyond the
arly polyadenylation signal and so is unlikely to be
uthentic. The three remaining ORFs are shown in Figure
a. Note that E5b and E5c are in the same reading frame
nd are separated by a single stop codon. E5a contains
o methionine residues, whereas E5b has a single me-
hionine residue 22 amino acids from the carboxyl-termi-
us. E5c contains a methionine residue 23 amino acids
rom the amino-terminus, potentially encoding a 47-
and the beginning of L2. One potential ORF that extends beyond the
ntains no methionine residues, and E5b has its only methionine near
three reading frames. (b) The sequence of the putative 47-amino-acid
E5 protein. No alignment is performed because the two proteins haved of E2
E5a co
ate the
BPV 1long hydrophobic stretch (boxed).
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168 BROWN ET AL.mino-acid protein. In addition, the three nucleotides
mmediately upstream from the methionine codon are
CT, similar to the ACC sequence that is preferred for
ibosome internal initiation (Kozak, 1986a, 1986b). Al-
hough this potential protein has no homology to any
nown E5 protein, it does contain a large hydrophobic
omain (16 consecutive residues of leucine, isoleucine,
r valine) similar to the 44-amino-acid bovine papilloma-
irus type 1 E5 protein (13 consecutive residues of
eucine, phenylalanine, or valine) (Schlegel et al., 1986)
Fig. 3b). We propose that the region labeled E5c is likely
o encode the authentic HPV 83 E5 protein.
haracterization of the E1^E4, E5 transcript
To further characterize the predictions based on the
equence, we identified a potential splice donor at nu-
leotide 733 and splice acceptor at nucleotide 3226 that
ould be utilized to produce an E1^E4, E5 transcript. The
1^E4, E5 transcript is produced in abundance in tissue
nfected with HPV 11 (Nasseri et al., 1987; Rotenberg et
l., 1989a, 1989b; Stoler et al., 1990) and several other
PV types (Doorbar et al., 1991; Pray and Laimins, 1995).
his assumption predicts that PCR primers located at
ucleotides 635 and 4063 should produce a cDNA am-
limer of 935 bp from the spliced transcript. If there were
ther splicing events involving some of the other poten-
ial ORFs in the E5 region, additional products might be
roduced. PCR primers located at 635 and 4063 were
sed to copy and amplify RNA purified from human
oreskin implants infected with HPV 83 stock virus.
An amplimer of the predicted size (935 bp) was visu-
lized by ethidium bromide staining of an agarose gel
Fig. 4a). The amplimer was excised from the gel, cloned
nto pCR3.1 (InVitrogen Corp., Carlsbad, CA), and se-
uenced to confirm the location of the splice site. The
equences of the cloned cDNA around the splice site as
ell as the genomic sequences surrounding the splice
onor and acceptor sites are shown in Figure 4b.
he long control region
The sequence between the end of the L1 ORF and the
FIG. 4. (a) A 1% agarose gel of the E1^E4, E5 cDNA amplimer show
n the absence of reverse transcriptase. (b) Sequence of a portion of th
1 start codon is underlined. The AG splice donor is at nucleotide 733,
equences surrounding the splice site are shown above the amplimereginning of the E6 ORF is called the long control region pLCR) because it contains many of the cis-acting regula-
ory sequences that control transcription and replication.
he LCRs of HPV types 11, 16, 18, and 31 are 673, 833,
26, and 954 bp long, respectively. The LCR of HPV 83 is
51 bp in length, making it one of the longest among
PVs. The combination of a long E5 region and a long
CR accounts for nearly all of the additional ;200 bp of
NA in HPV 83 compared with other HPVs.
One of the elements present in papillomavirus LCRs is
he origin of DNA replication. The origin sequence typi-
ally contains two E2 binding sites (ACCN6GGT) with an
1 binding site between (Lu et al., 1993; Mendoza et al.,
995; Sedman and Stenlund, 1995; Spalholz et al., 1993;
un et al., 1996). The HPV 83 LCR contains three E2
inding sites, including sites at 7958 and 8037 that con-
ain an E1 binding site between them. This site probably
epresents the HPV 83 origin of DNA replication. It is
hown aligned with other origin sequences in Figure 5a.
Papillomavirus LCRs also contain multiple binding
ites for transcriptional regulatory factors such as Oct-1,
P-1, and Sp1, among others. The HPV 83 LCR has many
f these putative binding sites that are consistent with
hose found in other papillomaviruses; these sites in-
lude TATA boxes at positions 8061 and 8067, just up-
tream from the beginning of the E6 ORF at position 8071
nd 43 and 37 bp upstream from the E6 initiation codon
t position 1. The predicted locations of these sites are
hown in Figure 5b. The HPV 83 LCR differs somewhat
rom that of other HPV LCRs by having only one E2
inding site near the probable E6 start site, but it is
imilar to other HPVs because the promoter-proximal E2
ite partially overlaps two Sp1 sites (Rapp et al., 1997).
nlike many HPV LCRs, HPV 83 contains no YY-1 binding
ites and no glucocorticoid responsive elements.
DISCUSSION
The diversity of HPV types provides an opportunity for
better understanding of virus–host interaction. Be-
ause different HPV types have somewhat different ef-
ects on normal and abnormal cell growth, an examina-
ion of differences and similarities among HPV types can
predicted product of 935 bp in lane 1. Lane 2 shows the PCR product
4, E5 amplimer showing the splice site at the predicted location. The
e CA splice acceptor is at nucleotide 3226, as indicated. The genomic
nce.ing the
e E1^E
and throvide insight into some of these complex processes.
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169HPV 83 NUCLEOTIDE SEQUENCEowever, the lack of a useful culture system that pro-
uces large amounts of virus and viral proteins makes
uch studies difficult. The human foreskin xenograft sys-
em (Kreider et al., 1986) permits the production of large
mounts of infected tissue, large amounts of infectious
irus, and large amounts of viral protein. Only HPV 11
Kreider et al., 1986), HPV 16 (Bonnez et al., 1998), HPV 40
Christensen et al., 1997), and HPV 83 (Brown et al., 1998)
ave been successfully propagated in the human fore-
kin xenograft system. We have cloned and sequenced
he genome of the HPV type most recently propagated in
his system.
HPV 83 is potentially of interest because it has been
dentified in about 1% of clinical specimens from patients
ith normal cytology and from 0.1–5.2% of patients with
ysplasia and cancer (Becker et al., 1994; Bosch et al.,
995; Schiffman et al., 1993). HPV 83 was one of the most
ommon types identified in women with HIV infection in
ne study, accounting for 13.3% of all HPV positives
Shah et al., 1997). It has also been shown to infect 3% of
ollege women who acquire new HPV infections each
ear (Ho et al., 1998). The fact that HPV 83 has been
dentified in some specimens from patients with cervical
FIG. 5. (a) Predicted origin of HPV 83 DNA replication shown aligned
re E2 binding sites (ACCN6GGT), and the middle sequence is the E
redicted cis elements in the HPV 83 LCR. The sites shown are those w
s calculated by the MATInspector program (Quandt et al., 1995).ysplasia and cancer suggests that it probably is not a qow-cancer-risk HPV type. The predicted E7 oncoprotein
f HPV 83 has structural features similar to the high-risk
PV types. Some histological features of the HPV 83-
nfected human foreskin implants also suggest that this
irus is capable of causing dysplasia (Brown et al., 1998;
rown and Fife, unpublished observations). For these
easons, we suggest that HPV 83 be considered an
ntermediate cancer risk virus pending additional char-
cterization of the virus, its proteins, and its epidemiol-
gy.
The DNA sequence of HPV 83, although typical of
apillomaviruses in general, has several unique fea-
ures. First, HPV 83 has the largest genome of all se-
uenced HPVs and it is larger than all except a few
nimal papillomaviruses [e.g., deer papillomavirus, 8374
p (Groff and Lancaster, 1985) and canine oral papillo-
avirus, 8607 bp (Delius et al., 1994)]. The size difference
s primarily due to a relatively long region between the
nd of the E2 ORF and the beginning of the L2 ORF (the
E5” region) and a comparatively long LCR. Because the
riginal genome cloning was done after first PCR ampli-
ying the entire genome, we independently PCR ampli-
ied each of these regions from genomic DNA and se-
veral other papillomavirus ori sequences. The sequences on the ends
ing site. Each dot represents one nucleotide. (b) Position of several
greatest degree of homology to consensus sequences for those siteswith se
1 bind
ith theuenced them to exclude artifacts in the original ampli-
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170 BROWN ET AL.ication. These sequences were identical to those
btained from the cloned, full-length DNA (data not
hown). This is not surprising because the original am-
lification was done using a system designed to mini-
ize amplification errors. It is puzzling that the long E5
egion of HPV 83 does not contain an easily identified E5
RF. The most likely candidate for an authentic E5 cod-
ng sequence occupies only about one fourth of the E5
egion. However, because of the sequence surrounding
he potential initiation site and the general similarity of
his candidate HPV 83 E5 protein to the bovine papillo-
avirus (BPV) 1 E5 protein, it is likely to be the authentic
roduct. The putative HPV 83 E5 protein lacks two fea-
ures of the BPV 1 E5 protein that make the comparison
ess certain. First, the HPV 83 protein contains no cys-
eine residues and so cannot exist as a disulfide-linked
imer as is thought to be important for the BPV protein
Burkhardt et al., 1987; Horwitz et al., 1988). Second, the
PV 83 protein does not contain a glutamine residue
djacent to the hydrophobic domain, a feature critical to
he function of the BPV protein (Klein et al., 1998). Bio-
ogical characterization of this and other predicted HPV
3 proteins will be important to determine the true func-
ions. Neither of the two most closely related HPV types
HPV 61 and 72) has an apparent E5 ORF, including a
PV-like E5. It is unlikely that any of the other potential
RFs in the E5 region of HPV 83 encode any proteins
nless there is an unrecognized splice site that joins one
f these sequences with an upstream ORF. However, our
mplification and cloning of the E1^E4, E5 cDNA did not
eveal any unexpected splice sites.
The HPV 83 E4 ORF also varies from other HPVs in the
ay that the E1^E4 spliced product (possibly the only
uthentic gene product of the E4 ORF) is constructed. For
xample, in HPV 11, the E1^E4 splice occurs in the fifth
odon downstream from the E4 initiation codon (Nasseri
t al., 1987). In contrast, the HPV 83 splice acceptor is at
ucleotide 3226, in the 15th codon downstream from the
ost proximal in-frame methionine codon at nucleotide
191. The significance of this difference is not certain, but
t does raise the possibility that an E4 gene product that
s significantly different from the E1^E4 gene product
ould be produced.
Despite its increased size, the HPV 83 LCR does not
ontain any recognizable novel cis elements. In fact, the
PV 83 LCR has fewer of some elements (e.g., E2 bind-
ng sites) than most HPVs and lacks other features (e.g.,
Y-1 sites and glucocorticoid responsive elements) that
re common in many HPVs. HPV 83 does appear to have
ll of the essential elements such as the probable origin
f DNA replication and standard promoter elements.
HPV 83 is a relatively prevalent genital tract papillo-
avirus in a variety of patient populations, including
atients with HIV infection. Based on the known epide-
iology of HPV 83 and the structure of the putative E7rotein, HPV 83 should be considered to be at least an tntermediate-risk HPV type. There are several unique
eatures of this virus including a probable BPV-like E5
rotein and an unusual structure of the E4 ORF splice
cceptor site that may merit further investigation. Such
tudies should be possible because HPV 83 is one of the
ew HPVs that can be grown under controlled conditions
n the laboratory.
MATERIALS AND METHODS
mplification and cloning of HPV 83 DNA
The full-length HPV 83 genome was amplified from a
uman foreskin implant recovered from an athymic
ouse as previously described (Brown et al., 1998).
riefly, PCR primers overlapping a unique BamHI site in
he 452-bp consensus primer target region of the ge-
ome (Manos et al., 1989) were designed and used to
mplify the entire genome using a proofreading, thermo-
table polymerase (Pwo). The ;8-kb PCR product was
loned into the cosmid vector Expand Vector 1 (Boehr-
nger-Mannheim, Indianapolis, IN).
equencing strategy
The sequence of the HPV 83 insert was determined by
tarting in the vector sequence at both ends and “walk-
ng” through the insert using primers designed from the
ost recent sequence in that direction. Sequencing was
one on an ABI Prism Model 377 automated sequencer
Perkin–Elmer Applied Biosystems, Foster City, CA). A
otal of 32 sequencing primers were used for the primary
equence determination. The overlapping sequence
ragments were assembled manually and confirmed
rom the complementary strand. Several additional prim-
rs were used to clarify sequence ambiguities. In addi-
ion, segments in the E5 region and LCR were amplified
nd subcloned from infected tissue and sequenced to
erify the sequence obtained from the original clone.
Once assembled, the sequence was analyzed for ho-
ology to other HPVs using the basic local alignment
equence tool (BLAST) software (Altschul et al., 1997).
he same software was used to determine protein se-
uence homologies. The long control region was
earched for cis elements using the MATInspector soft-
are (Quandt et al., 1995).
outhern blots
DNA was extracted from foreskin implants and South-
rn blots performed as previously described (Brown et
l., 1993, 1998; Southern, 1975), except that a 0.6% aga-
ose gel was used. A mixture of cloned, linearized HPV
1 and HPV 83 DNA was labeled with [a-32P]dATP by nick
ranslation and used as a probe for the blot.
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171HPV 83 NUCLEOTIDE SEQUENCEmplification and cloning of the E1^E4, E5 spliced
ranscript
Total RNA was isolated as previously described from
he viable capsule tissue on an athymic mouse human
oreskin xenograft infected with the HPV 83 extract and
rown for 4 months (Brown et al., 1996). Reverse tran-
cription was performed followed by a PCR using prim-
rs designed to amplify a predicted E1^E4 spliced tran-
cript (59 primer GTGTGAAGACGCAGACCTAA, position
35–654; 39 primer GAATGGCTGGTTGTGTGGTT, posi-
ion 4044–4063).
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